Hefty price tag for unvaccinated COVID hospitalizations

Hospital costs for unvaccinated COVID-19 patients can average $20,000, according to a Kaiser Family Foundation (KFF) study.

“While real-time data on the cost of all COVID-19 hospitalizations are not publicly available, various sources point to an average hospitalization cost of around $20,000. The Centers for Medicare and Medicaid Services (CMS) reports that Medicare fee-for-service COVID-19 hospitalizations average $24,033,” wrote the study authors.

Analysis of CDC data showed that between June and July there was a total of 113,00 preventable COVID hospitalizations among unvaccinated adults in the U.S. at a cost of $2 billion dollars.

The authors cited several studies detailing the costs associated with COVID hospitalizations.

For example, a study of Medicare fee-for-service enrollees found an average COVID hospitalization cost $21,752 while A FAIR Health analysis of private claims data including employer and private Medicare Advantage plans found that COVID hospitalization costs ranged from $17,094 for people over age 70 to $24,012 for people in their 50s.

In a KFF analysis, pre-pandemic private insurance claims for pneumonia hospitalizations with complications averaged $20,292 and when a hospitalized patient needed a ventilator, the costs were even higher.

“The monetary cost of treating unvaccinated people for COVID-19 is borne not only by patients but also by society more broadly, including taxpayer-funded public programs and private insurance premiums paid by workers, businesses, and individual purchasers,” wrote the study authors.

Read the report here.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.